TenNor Therapeutics, a clinical-stage biotech firm specialised in the discovery and development of new drug products targeting bacterial infection and metabolic diseases, has secured 300 million yuan ($42.1 million) in the first close of its Series E round.
Continue reading with Data Vantage
Venture-backed company data in SE Asia, India, Pakistan, Bangladesh.
Instant investment updates and valuations.
Tailored search, 3 monthly reports.
Industry-trusted platform.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com